Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Cattaneo, C; Salmanton-García, J; Marchesi, F; El-Ashwah, S; Itri, F; Weinbergerová, B; Gomes, Da, Silva, M; Dargenio, M; Dávila-Valls, J; Martín-Pérez, S; Farina, F; Van, Doesum, J; Valković, T; Besson, C; Poulsen, CB; López-García, A; Žák, P; Schönlein, M; Piukovics, K; Jaksic, O; Cabirta, A; Ali, N; Sili, U; Fracchiolla, N; Dragonetti, G; Adžić-Vukičević, T; Marchetti, M; Machado, M; Glenthøj, A; Finizio, O; Demirkan, F; Blennow, O; Tisi, MC; Omrani, AS; Navrátil, M; Ráčil, Z; Novák, J; Magliano, G; Jiménez, M; Garcia-Vidal, C; Erben, N; Del, Principe, MI; Buquicchio, C; Bergantim, R; Batinić, J; Al-Khabori, M; Verga, L; Szotkowski, T; Samarkos, M; Ormazabal-Vélez, I; Meers, S; Maertens, J; Pinczés, LI; Hoenigl, M; Drgoňa, Ľ; Cuccaro, A; Bilgin, YM; Aujayeb, A; Rahimli, L; Gräfe, S; Sciumè, M; Mladenović, M; Çolak, GM; Sacchi, MV; Nordlander, A; Berg, Venemyr, C; Hanáková, M; García-Poutón, N; Emarah, Z; Zambrotta, GPM; Nunes, Rodrigues, R; Cordoba, R; Méndez, GA; Biernat, MM; Cornely, OA; Pagano, L.
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey.
Cancers (Basel). 2022; 14(22): Doi: 10.3390/cancers14225530 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

Hönigl Martin

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

BACKGROUND: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. METHODS: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. RESULTS: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. CONCLUSIONS: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

Find related publications in this database (Keywords)

haematological malignancy onset

COVID-19

treatment

outcome

prognostic factors

© Med Uni Graz • Imprint